The GMDx TSM test identifies the source of mutation(s) and provides an indication of the IIF profile that is unique for each individual with additional data to guide the selection of treatment(s). TSM testing can be applied in oncology at all stages. Current genomic tests based on cancer panels, tumour mutation burden, ctDNA, miRNA, and other biomarkers are limited in their ability to predict response to immunotherapies; the TSM test provides a unique alternative to these methods.
The key advantages of the TSM test are:
- Identifies the SOURCE of endogenous and exogenous mutagens giving rise to disease;
- Identifies the genomic context of the mutations; and,
- Provides clinically relevant insights into links between a patient’s IMMUNE FUNCTION and disease progression